GPPAD

GPPAD

The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) is a consortium of several academic research institutions and clinics in Europe with the goal of establishing an international infrastructure for studies to prevent the development of type 1 diabetes.

Further information: www.gppad.org

All studies in GPPAD:

Freder1k study

Freder1k: Early detection of type 1 diabetes risk

The Freder1k study examines newborns and babies up to the age of four months in Bavaria, Lower Saxony, Saxony and Thuringia for an increased genetic risk of type 1 diabetes. The test is free of charge and can be carried out at the birth clinic or the pediatrician's office. 

Information flyer for download

Further informationen: www.freder1k-studie.de 

POInT study

POInT: Acting preventively

The POInT (Primary Oral Insulin Trial) study aims to prevent the destruction of pancreatic insulin-producing cells in children with an increased risk of type 1 diabetes and thus the development of type 1 diabetes. Children aged  4 to 7 months can participate in the study and receive insulin powder or a placebo daily with their diet until their 3rd birthday.

Information flyer for download

Further informationen: www.point-studie.de